Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 20;25(18):4314.
doi: 10.3390/molecules25184314.

Mast Cell Regulation and Irritable Bowel Syndrome: Effects of Food Components with Potential Nutraceutical Use

Affiliations
Review

Mast Cell Regulation and Irritable Bowel Syndrome: Effects of Food Components with Potential Nutraceutical Use

José Antonio Uranga et al. Molecules. .

Abstract

Mast cells are key actors in inflammatory reactions. Upon activation, they release histamine, heparin and nerve growth factor, among many other mediators that modulate immune response and neuron sensitization. One important feature of mast cells is that their population is usually increased in animal models and biopsies from patients with irritable bowel syndrome (IBS). Therefore, mast cells and mast cell mediators are regarded as key components in IBS pathophysiology. IBS is a common functional gastrointestinal disorder affecting the quality of life of up to 20% of the population worldwide. It is characterized by abdominal pain and altered bowel habits, with heterogeneous phenotypes ranging from constipation to diarrhea, with a mixed subtype and even an unclassified form. Nutrient intake is one of the triggering factors of IBS. In this respect, certain components of the daily food, such as fatty acids, amino acids or plant-derived substances like flavonoids, have been described to modulate mast cells' activity. In this review, we will focus on the effect of these molecules, either stimulatory or inhibitory, on mast cell degranulation, looking for a nutraceutical capable of decreasing IBS symptoms.

Keywords: cannabidiol; fatty acids; heparin; histamine; irritable bowel syndrome; mast cells; nerve growth factor; nutraceuticals; polyphenols; visceral pain.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Schematic representation of the modulatory activity of food components on mast cells and their relationship with the generation and modulation of irritable bowel syndrome (IBS)-related symptoms. The figure integrates the main bioactive food components with potential nutraceutical use (as discussed in the text), the main mechanisms of action proposed on mast cells and some of the key symptoms related to IBS that can be modulated through the action of mast cell-derived mediators. See text for details. The photomicrographs (right) show mast cells in the rat intestine, identified with toluidine blue staining (upper photomicrograph) and rat mast cell protease 2 immunohistochemistry (lower photomicrograph). Scale bar: 20 μm.

References

    1. Black C.J., Ford A.C. Global burden of irritable bowel syndrome: Trends, predictions and risk factors. Nat. Rev. Gastro. Hepat. 2020;17:473–486. doi: 10.1038/s41575-020-0286-8. - DOI - PubMed
    1. Grad S., Dumitrascu D.L. Irritable Bowel Syndrome Subtypes: New Names for Old Medical Conditions. Dig. Dis. 2020;38:122–127. doi: 10.1159/000505287. - DOI - PubMed
    1. Creed F. Review article: The incidence and risk factors for irritable bowel syndrome in population-based studies. Aliment Pharm. Therap. 2019;50:507–516. doi: 10.1111/apt.15396. - DOI - PubMed
    1. Canavan C., West J., Card T. Review article: The economic impact of the irritable bowel syndrome. Aliment Pharm. Therap. 2014;40:1023–1034. doi: 10.1111/apt.12938. - DOI - PubMed
    1. Spiller R., Major G. IBS and IBD-separate entities or on a spectrum? Nat. Rev. Gastro. Hepat. 2016;13:613–621. doi: 10.1038/nrgastro.2016.141. - DOI - PubMed

MeSH terms